Last reviewed · How we verify
ESG401
ESG401 is an investigational drug in phase 3 development by Qilu Pharmaceutical, but its specific mechanism of action is not publicly disclosed.
At a glance
| Generic name | ESG401 |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without access to detailed clinical trial data or published mechanism information, the precise molecular target and pharmacological action of ESG401 cannot be reliably determined. Phase 3 status indicates it has progressed through early safety and efficacy testing, but mechanism details remain proprietary or unpublished.
Approved indications
Common side effects
Key clinical trials
- A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer (PHASE3)
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (PHASE2)
- Study of ESG401 in Adults With Solid Tumors (PHASE1, PHASE2)
- A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ESG401 CI brief — competitive landscape report
- ESG401 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI